Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | LSS | P48449 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2726596 | 0.88 | CA12 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20294563 | 0.82 | TSHR (0.46) | DRD4DRD2DRD3MAOB | |
| SCHEMBL16519364 | 0.81 | MMP2 (0.39) | CA12CA1CA2CA7CA9 | |
| SCHEMBL98740 | 0.78 | DRD4 (0.47) | APPDRD4DRD2DRD3MAOB | |
| SCHEMBL24933380 | 0.77 | APP (0.50) | APPRXRARXRBCA12CA1 | |
| SCHEMBL794717 | 0.77 | DRD4 (0.43) | APPDRD4DRD2DRD3MAOB | |
| SCHEMBL2561524 | 0.77 | ALDH1A1 (0.44) | APPDRD4DRD2DRD3MAOB | |
| SCHEMBL10972893 | 0.77 | LTA4H (0.47) | APPDRD4DRD2DRD3 | |
| SCHEMBL2559715 | 0.77 | ALDH1A1 (0.52) | — | |
| SCHEMBL20442679 | 0.77 | NQO1 (0.64) | POLBCA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0357348-B1 | Process for preparing p-bromophenoxyacetaldehyde dialkylacetal derivatives | UBE INDUSTRIES (JP) | 1994-06-08 | — | — | EP | claimed |
| US-4982008-A | Process for preparing p-bromophenoxyacetaldehyde dialkylacetal compounds | UBE INDUSTRIES, LTD. (JP) | 1991-01-01 | — | — | US | claimed |
| EP-0357348-A2 | Process for preparing p-bromophenoxyacetaldehyde dialkylacetal derivatives | UBE INDUSTRIES, LTD. (JP) | 1990-03-07 | — | — | EP | claimed |
| US-20240360082-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| EP-3978472-B1 | BIARYL MONABACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-108368040-B | Diaryl monocyclic beta-lactam compounds and methods for their use in the treatment of bacterial infections | 默沙东有限责任公司 | 2024-08-23 | — | — | CN | disclosed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| EP-0357348-A3 | PROCESS FOR PREPARING P-BROMOPHENOXYACETALDEHYDE DIALKYLACETAL DERIVATIVES | UBE INDUSTRIES, LTD. (JP) | 1991-07-17 | — | — | EP | disclosed |
| US-5030755-A | Process for producing substituted phenoxyethylamines and intermediates | UBE INDUSTRIES LTD. (JP) | 1991-07-09 | — | — | US | disclosed |
| US-4985596-A | FROM PHENOXYACETALDEHYDE DIALKYL ACETAL AND A HYDROXYLAMINE | UBE INDUSTRIES, LTD. (JP) | 1991-01-15 | — | — | US | disclosed |
| US-4982008-A | Process for preparing p-bromophenoxyacetaldehyde dialkylacetal compounds | UBE INDUSTRIES, LTD. (JP) | 1991-01-01 | — | — | US | disclosed |
| US-4982008-A | Process for preparing p-bromophenoxyacetaldehyde dialkylacetal compounds | UBE INDUSTRIES, LTD. (JP) | 1991-01-01 | — | — | US | disclosed |
| US-4982008-A | Process for preparing p-bromophenoxyacetaldehyde dialkylacetal compounds | UBE INDUSTRIES, LTD. (JP) | 1991-01-01 | — | — | US | disclosed |
| EP-0357310-A1 | Process for producing substituted phenoxyethylamines and intermediates | UBE INDUSTRIES, LTD. (JP) | 1990-03-07 | — | — | EP | disclosed |
| EP-0357348-A2 | Process for preparing p-bromophenoxyacetaldehyde dialkylacetal derivatives | UBE INDUSTRIES, LTD. (JP) | 1990-03-07 | — | — | EP | disclosed |
| EP-0357348-A2 | Process for preparing p-bromophenoxyacetaldehyde dialkylacetal derivatives | UBE INDUSTRIES, LTD. (JP) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360082-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | PNPO, PDXK, PLPBP | PPARD 2041/4885APP 4490/4885DRD4 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.